Biopharma Middle East and Africa (Biopharma-mea) today announced that it has entered into an exclusive agreement with LEO Pharma to commercialize the Thrombosis Portfolio in Saudi Arabia.

 

Biopharma views this collaboration with LEO Pharma as a significant stride towards enhancing patient care in Saudi Arabia. By continuing to commercialize the Thrombosis Portfolio into the Saudi market, we aim to address the need for treatment options in the field of thrombosis. This partnership aligns with our commitment to bringing healthcare solutions to the region, ensuring that patients have access to more treatment options. We believe that by making the Thrombosis Portfolio available, we are not only offering a therapeutic option but also contributing to overall healthcare in Saudi Arabia.​

​

About Biopharma-mea

Biopharma, a pharmaceutical company based in the Middle East, specializes in niche and biotech pharmaceutical products, committed to delivering high-quality solutions and addressing the unmet needs of patients. The company has made its mark across the Middle East by offering treatments for rare, life-threatening genetic disorders such as Cystic Fibrosis, Mucopolysaccharidosis, Phenylketonuria, Neuronal Ceroid Lipofuscinosis Type 2, Sickle Cell Disease, Haemophilia, and more. Additionally, Biopharma holds a significant position in the infectious disease market, providing curative treatments for Hepatitis C Virus and innovative medicines for managing Human Immunodeficiency Virus and Hepatitis B Virus.

Founded in 2007 and headquartered in Dubai, UAE, Biopharma strategically operates within the Middle East, partnering with local distributors and wholesalers to maximize patient outreach and establish strong connections throughout the healthcare sector. The company is dedicated to offering the best healthcare solutions, aiming to bridge the care gap with a deep understanding of both national and regional healthcare requirements. For updates and more information about Biopharma, please visit our website at www.biopharma-mea.com or follow us on Facebook, Twitter, LinkedIn, and Instagram.

​

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with Skin Conditions and Thrombosis, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of Dermatology and Thrombosis. Today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.

​

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our partnership with LEO Pharma, anticipated benefits and synergies of the partnership, future opportunities for the company, and any other statements regarding our future expectations, beliefs, plans, objectives, financial conditions, assumptions, or future events or performance. These statements are often, but not always, made through the use of words or phrases such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'projects,' 'forecasts,' 'may,' 'will,' 'should,' 'could,' and similar expressions.

All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that Biopharma-mea or LEO Pharma will realize these expectations or that these beliefs will prove correct. Numerous factors could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties such as changes in market conditions, the failure to realize the anticipated benefits of the partnership, and other economic, business, competitive, and/or regulatory factors affecting the business of Biopharma-mea and LEO Pharma generally.

​

Biopharma-mea expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in the expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as required by law."